Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial

The Lancet Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles